This article was originally published by James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr & David A Brindley in Nature Biotechnology v35, pp 210–214 (2017) under a creative…
This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
Diffusion, convergence and influence of pharmaceutical innovations: a comparative study of Chinese and U.S. patents
0
This paper was originally published by Qiaolei Jiang and Chunjuan Luan in Globalization and Health 2018 14:92 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). Abstract Background Despite the significant impact…
Patents filed since 1995 last for 20 years from the date of patent application filing. This is true for “utility” patents, but the terms for certain other, less common types…
Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges
0
This article was originally published by Basavaraj S, Guru V. Betageri in Acta Pharmaceutica Sinica B Volume 4, Issue 1, February 2014, Pages 3-17 under a Creative Commons License. Abstract Drug discovery and development…
Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
0Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
This paper was originally published by T. Joseph Mattingly, Joseph F. Levy, Julia F. Slejko, Nneka C. Onwudiwe, and Eleanor M. Perfetto in PharmacoEconomics Volume 36, Issue 9 under a Creative Commons…
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
0
This paper was originally published by Toon van der Gronde, Carin A. Uyl-de Groot, and Toine Pieters in PLoS ONE 12(8): e0182613 under a creative commons license. Abstract Context Recent public outcry…
The theoretical construct of what happens when drug patents expire is simple and appealing (to consumers, anyway). A name brand drug patent expires, generics are waiting in the wings to…
This paper was originally published by Harinder Singh Chahal, Jeffrey S Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, and Peter G Lurie in Journal of the International AIDS…
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
0
This paper was originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017 under a …